Smallpox

Smallpox

Biodefense Headlines – April 30, 2026

News Scan April 30, 2026

This week’s selections include cascading institutional disruptions reshaping U.S. public health and science governance — including the Trump administration’s mass firing of the National Science Board and restrictions on graduate…

Smallpox Research Blurs Line Between Ancient Diseases, Emerging Infections

Intravenous Brincidofovir May Improve Countermeasure’s Tolerability

Bavarian Nordic Provides 2016 Update

Canadian Government Orders Additional Smallpox Vaccine

PharmAthene Receives 5M Initial Payment from SIGA

Phase 1 Trial Begins for IV Version of Smallpox Drug

SIGA Gets Greenlight on Smallpox Drug Phase 3 Trial

U.S. Government Places 133M Smallpox Vaccine Order

U.S. Moves Forward with Stockpiling of Second Smallpox Antiviral

Smallpox Vaccine Performs Well in Two Pivotal Studies

Misconceptions About Smallpox’s Role in Native Depopulation

Smallpox Vaccine Virus Helps UNL Scientist Understand Immunity

PharmAthene Awarded $195M+ in SIGA Smallpox Lawsuit

Chimerix Speeding Up Brincidofovir Trials for Ebola

Chimerix EIND Authorized for Patients with Ebola Virus

Emergent BioSolutions Awarded 19M for Smallpox Drug

Transcript of CDC Press Conference on Biosafety Incidents

Smallpox Vials Discovered in NIH Storage Room

Scientists Again Call for Delay in Destruction of Last Stocks of Smallpox

Children Conceived During Epidemic Have More Lifetime Resistance

Biodefense Headlines – April 30, 2026